Skip to main content

Alkem lab share Q4 results 2021 | Business Updates | best stocks to buy today

 


              Alkem laboratories ltd


Q4&FY21 Business Updates


Overview - Alkem laboratories is established in 1973.Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India that manufactures and sells pharmaceutical generics, formulations and nutraceuticals in India and globally.


Q4-FY21 Financial Highlights - 


* Revenue from Operations - 


* Revenue from India - 


* Revenue from Outside - 


* EBITDA And EBITDA Margins - 


* Profit After Tax - 


 FY21:Key Financial Highlights 



Indian Business - 

• India sales contributed 68.1% to total sales in Q4FY21

• Company witnessed good recovery in the second half of the financial year compared to YoY decline in the first half

• Company’s Trade Generic business delivered a robust growth during the quarter and the financial year

• In Q4FY21, the Company’s secondary sales grew by 9.8% YoY compared to IPM growth of 8.5% YoY (Source: IQVIA data)

• During the quarter, the Company grew ahead of the market in the therapy areas of anti-infectives, pain management, vitamins / minerals / nutrients, neuro / CNS, cardiac and anti-diabetes (Source: IQVIA 


* Revenue from India Business - 


* Revenue From Segments - 




US Business - 

• US sales contributed 25.1% to total sales in Q4FY21
• Company’s US sales doubled in four years through FY17 to FY21 registering a CAGR of 19.5% led by new product launches and
market share gain in existing products
• In FY21, the Company filed 9 ANDAs with the US FDA and received 25 approvals (including 6 tentative approval)
• As on March 31, 2021, the Company has filed a total of 152 ANDAs (including 2 NDAs) with the US FDA and has received 110 approvals (including 16 tentative approvals and 2 NDAs)

* Revenue from US Business - 




Other International Business - 

• Other International Market sales contributed 6.8% to total sales in Q4FY21
• The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS
• Chile, Kazakhstan and UK registered healthy growth during the year

* Revenue from Other International Business - 


 


Latest Shareholding Pattern (as per March 2021) 


 

Some Extra Information - 

• R&D expenses in FY21 was at 6.0% of revenue from operations compared to 5.7% in FY20

• The Company filed 9 ANDAs with the US FDA and received 25 approvals (including 6 tentative approval) in FY21

• Healthy Balance Sheet with net cash of ₹ 5.3bn as on March 31, 2021

Labels:
Location: India

Comments

Post a Comment

Popular posts from this blog

RACL Geartech stock analysis | Fundamental analysis | Best micro cap stock to invest

    Fundamental Analysis of Racl Geartech 1 .  Company and its industry  2.  Management and its business model 3.  Fundamentals 4.  Growth  5.  Valuation ————————————————                               Company Overview  - RACL is established in 1989 for producing automotive components in the field of motorcycle & scooter, 3&4 vehicles, cargo vehicles, agriculture machinery, tractor, ATV, light & heavy commercial vehicles, etc. * Share- holding pattern -  * Subsidiary -  RACL Geartech GmbhH ( Austria) || 100% holding. * Extra information 1. CSR expenditure - 20.55 lakhs 2. Salary to employees - 24.82 crore                                          Industry * India is the 5th largest auto market in the world. * India is the 7th largest manufacturer of commercial vehicles. * The Indian auto components industry has experienced healthy growth over the last few years  * In 2018-2019, the turnover of the Indian auto components industry was 3,95,902 crore. Its contribution to GDP
1 comment
Read more

Au small finance bank share Q4&FY21 Business Updates | q4 result | au small finance bank news

                 AU SMALL FINANCE BANK   Q4&FY21 BUSINESS UPDATES   Key Q4FY21 Highlight -  Q4FY21 Quarterly Result -  Key FY21 Financial Highlights -  FY21 Annual Result -  Other Income Statement -  Balance Sheet -  Assets & Liabilities Breakup -  Key FY21 Operational Highlights -  ➢ Strong rebound in disbursement in H2 (Vehicle, SBL and Housing)  ➢ 77% of total FY21 disbursement in H2 (47% YoY growth) ➢ Deposits continue to scale driven by increasing brand awareness, branch expansion and improved digital offering ➢ Improved CASA ratio from 14% to 23% ➢ Overall Cost of Funds reduced by 86 bps to 6.83% from 7.69% in FY20 ➢ GNPA of ₹ 1,503 Cr (4.3%), of which ➢ >90DPD portfolio - ₹ 962 Cr (2.7%)  ➢ <90 DPD portfolio - ₹ 541 Cr (1.5%) ➢ Collection efficiency was >100% in each month of Q4FY21 ➢ PAT (ex-Aavas) grew YoY despite accelerated provisions in FY21 ➢ Deposit are at 35,979 crore ( Growth of 38%)(y-o-y) Share Holdings Pattern - 
Post a Comment
Read more

Jyoti Resins and Adhesives Q4&FY21 Business Updates

                Jyoti Resins and Adhesives ltd              Q4 & FY21 Business Updates   Company overview -  • JYOTI RESINS AND ADHESIVES LTD is a manufacturer of synthetic resin adhesives. The Company manufactures various types of wood adhesives (white glue) under the brand name of EURO 7000. • The company launched its brand “Euro7000” in 2006. • The company has steadily increased its plant (at Santej, Ahmedabad) capacity to 1000 Tonnes per month. • Euro 7000has today grown exponentially and is now the second largest (No2) selling wood adhesive (white glue) brand in India in the retail segment. •The company’s successs so far in this business is an outcome of its strategic vision focus on delivering world class products and services to its customers. • Today it a services 12 states in India through 20 branches and 50 distributors,cateringto 10,000 retailers and 3 lac carpenters across India. A 300 strong sales force plays a key role in this process. Q4&FY21 Financials  - (in m
Post a Comment
Read more